0903 [Dow Jones] STOCK CALL: Credit Suisse raises ResMed (RMD.AU) target to A$5.30 from A$5.20 after RMD 4Q08 earnings were ahead of CS' estimates, reflecting a return to U.S. growth. "Top line revenue growth was the standout - American sales increased 14% versus a year earlier, underpinned by faster-than-expected traction of recent product releases," CS says in a client note. Keeps Neutral. "We believe that the early success of recent product launches and a pipeline of high margin releases scheduled for FY09 augurs well for continued top line revenue growth at least in line with industry average (15%)." Still, CS remains concerned about 300 basis-point margin decline in the past year due to currency, product mix and price discounting. Last trade A$4.60. (ABH)
0903 [Dow Jones] STOCK CALL: Credit Suisse raises ResMed...
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$38.59 |
Change
0.480(1.26%) |
Mkt cap ! $22.38B | |||
| Open | High | Low | Value | Volume |
| $38.50 | $38.74 | $38.25 | $36.39M | 944.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 882 | $38.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $38.60 | 19192 | 6 |
View Market Depth
| Last trade - 16.10pm 28/11/2024 (20 minute delay) ? |
| RMD (ASX) Chart |
